The verdict
Our read at a glance.
Whether menotropins is understood as an approved, monitored fertility treatment that supplies both FSH and LH activity for ovarian stimulation, rather than a general hormone tool, and how it compares with pure recombinant FSH.
- The signal
- Decades of use and trials establish menotropins as effective for ovarian stimulation in IVF and for ovulation induction. Head-to-head studies against recombinant FSH show broadly similar pregnancy outcomes, with long-running debate over small differences.
- The unknown
- Whether the added LH activity or the urinary versus recombinant source meaningfully changes outcomes for particular patients, and how to individualize the choice and dose to limit hyperstimulation and multiple pregnancies.
- Our read
- A long-established fertility medicine: a purified FSH-plus-LH blend that reliably stimulates the ovaries for IVF, working about as well as recombinant FSH in most comparisons. The real considerations are careful monitoring to avoid ovarian hyperstimulation and multiple pregnancies, and matching product and dose to the patient, not any general hormone use.
The mechanism
How it works.
Growing eggs for IVF or triggering ovulation takes two pituitary hormones: FSH, which makes ovarian follicles grow, and LH, which helps them mature and make estrogen. Menotropins is a purified preparation of these gonadotropins, collected and cleaned up from the urine of postmenopausal women (whose bodies naturally pump out high levels of them), so it supplies both FSH and LH activity. Injected under the skin, it does the ovaries' usual job at controlled, often higher levels to grow several follicles at once. This is the urinary, FSH-plus-LH counterpart to follitropin, which is pure FSH made in cells; because it pushes the ovaries hard, the response is monitored closely to avoid over-stimulation.
Safety & regulatory boundary
The consequential part.
Like all gonadotropins, menotropins can cause ovarian hyperstimulation syndrome (swollen ovaries and dangerous fluid shifts in severe cases), multiple pregnancies, blood clots, and ovarian torsion, so treatment is closely monitored with ultrasound and blood tests. It is a prescription fertility medicine used under specialist supervision, not a general hormone or performance treatment, and it is a distinct product from recombinant FSH (follitropin).
What's next
What we're watching.
Individualized dosing to reduce hyperstimulation and multiple-pregnancy risk, and clearer evidence on when urinary FSH-plus-LH offers any advantage over recombinant FSH.
Context
Why this is discussed.
Menotropins is one of the original fertility drugs, a purified blend of the hormones (FSH and LH) that drive the ovaries. It is widely used to grow multiple eggs for IVF, and it represents the urinary-derived, FSH-plus-LH side of fertility stimulation, in contrast to pure recombinant FSH.
The evidence base
11 cited references.
Regulatory & labels1
Ferring Pharmaceuticals Inc. (FDA label) · 2018
Registered trials3
ClinicalTrials.gov · PHASE3 · RECRUITING · 2026-02-05
ClinicalTrials.gov · PHASE3 · RECRUITING · 2025-11-01
ClinicalTrials.gov · PHASE4 · COMPLETED · 2017-07-06
Indexed literature (PubMed)7
Melo P et al. · Cochrane Database Syst Rev · 2025
Weiss NS et al. · Cochrane Database Syst Rev · 2025
Witz CA et al. · Fertil Steril · 2020
Daya S · Cochrane Database Syst Rev · 2000
Van Wely M et al. · Cochrane Database Syst Rev · 2003
Agrawal R et al. · Fertil Steril · 2000
Levi Setti PE et al. · J Endocrinol Invest · 2015
Keep reading